Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial

Background  In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of 5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of apixaban drug levels, as determined by apixaban-calibrated anti-factor Xa (anti-Xa) activity, has previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhagirath, Vinai C., Eikelboom, John W., Hirsh, Jack, Coppens, Michiel, Ginsberg, Jeffrey, Vanassche, Thomas, Yuan, Fei, Chan, Noel, Yusuf, Salim, Connolly, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524853/
https://www.ncbi.nlm.nih.gov/pubmed/31249919
http://dx.doi.org/10.1055/s-0037-1613679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524853/
https://www.ncbi.nlm.nih.gov/pubmed/31249919
http://dx.doi.org/10.1055/s-0037-1613679

Ejemplares similares